Comfort Systems USA Inc vs Heron Therapeutics Inc — how do they compare? Comfort Systems USA Inc trades at $1,737 (market cap $60.06B), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: Comfort Systems USA Inc is far larger — about 883.1× Heron Therapeutics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and Heron Therapeutics Inc for 35 Days on average.
| FIX | HRTX | |
|---|---|---|
Market Cap | $60.06B | $68.01M |
Volume | 371,896 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $2.07K | $1.49 |
52-Week Low | $790.72 | $0.27 |
Typical Hold Time | 41 Days | 35 Days |
Enterprise Value | $58.53B | $174.75M |
Dividend Yield | 0.21% | — |
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages and support at $1,712. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $12.53 vs. $10.45, while revenue growth accelerates from $9.1B in 2025 to $11.2B in 2026. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
FIX presents a compelling growth opportunity with 55.56% analyst buy ratings and a $2,080 consensus price target offering 19% upside. Key risks include execution challenges in integrating acquisitions and potential margin pressure from rising costs. The stock's premium valuation (P/E 42) requires sustained earnings growth, but strong ROE (55.29%) and expanding data center backlog support the bullish case.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →